Clinical Efficacy and Molecular Dynamics of Quantum Molecular Resonance (QMR) Electrotherapy in Dry Eye Management

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Dry Eye Disease (DED)
Interventions
DEVICE

The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology

The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.

Trial Locations (1)

Unknown

The Hong Kong Polytechnic University, Hong Kong

All Listed Sponsors
lead

The Hong Kong Polytechnic University

OTHER

NCT06955806 - Clinical Efficacy and Molecular Dynamics of Quantum Molecular Resonance (QMR) Electrotherapy in Dry Eye Management | Biotech Hunter | Biotech Hunter